183 related articles for article (PubMed ID: 22248814)
1. Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1).
Liu-Sullivan N; Zhang J; Bakleh A; Marchica J; Li J; Siolas D; Laquerre S; Degenhardt YY; Wooster R; Chang K; Hannon GF; Powers S
Oncotarget; 2011 Dec; 2(12):1254-64. PubMed ID: 22248814
[TBL] [Abstract][Full Text] [Related]
2. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
[TBL] [Abstract][Full Text] [Related]
3. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
Pajtler KW; Sadowski N; Ackermann S; Althoff K; Schönbeck K; Batzke K; Schäfers S; Odersky A; Heukamp L; Astrahantseff K; Künkele A; Deubzer HE; Schramm A; Sprüssel A; Thor T; Lindner S; Eggert A; Fischer M; Schulte JH
Oncotarget; 2017 Jan; 8(4):6730-6741. PubMed ID: 28036269
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel.
Chou YS; Yen CC; Chen WM; Lin YC; Wen YS; Ke WT; Wang JY; Liu CY; Yang MH; Chen TH; Liu CL
Int J Oncol; 2016 Mar; 48(3):1187-94. PubMed ID: 26794530
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1.
Wu CP; Hsiao SH; Luo SY; Tuo WC; Su CY; Li YQ; Huang YH; Hsieh CH
Mol Pharm; 2014 Oct; 11(10):3727-36. PubMed ID: 25192198
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.
Tandle AT; Kramp T; Kil WJ; Halthore A; Gehlhaus K; Shankavaram U; Tofilon PJ; Caplen NJ; Camphausen K
Eur J Cancer; 2013 Sep; 49(14):3020-8. PubMed ID: 23790466
[TBL] [Abstract][Full Text] [Related]
7. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
[TBL] [Abstract][Full Text] [Related]
8. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
Hu K; Law JH; Fotovati A; Dunn SE
Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
[TBL] [Abstract][Full Text] [Related]
9. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
Shin SB; Woo SU; Yim H
J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
[TBL] [Abstract][Full Text] [Related]
10. PLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs.
Brassesco MS; Pezuk JA; Salomão KB; Roberto GM; Scrideli CA; Tone LG
Anticancer Agents Med Chem; 2018; 18(9):1252-1257. PubMed ID: 29493466
[TBL] [Abstract][Full Text] [Related]
11. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.
Lansing TJ; McConnell RT; Duckett DR; Spehar GM; Knick VB; Hassler DF; Noro N; Furuta M; Emmitte KA; Gilmer TM; Mook RA; Cheung M
Mol Cancer Ther; 2007 Feb; 6(2):450-9. PubMed ID: 17267659
[TBL] [Abstract][Full Text] [Related]
12. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
13. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
14. A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1.
Danovi D; Folarin A; Gogolok S; Ender C; Elbatsh AM; Engström PG; Stricker SH; Gagrica S; Georgian A; Yu D; U KP; Harvey KJ; Ferretti P; Paddison PJ; Preston JE; Abbott NJ; Bertone P; Smith A; Pollard SM
PLoS One; 2013; 8(10):e77053. PubMed ID: 24204733
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.
Harris PS; Venkataraman S; Alimova I; Birks DK; Donson AM; Knipstein J; Dubuc A; Taylor MD; Handler MH; Foreman NK; Vibhakar R
BMC Cancer; 2012 Mar; 12():80. PubMed ID: 22390279
[TBL] [Abstract][Full Text] [Related]
16. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.
Hu K; Lee C; Qiu D; Fotovati A; Davies A; Abu-Ali S; Wai D; Lawlor ER; Triche TJ; Pallen CJ; Dunn SE
Mol Cancer Ther; 2009 Nov; 8(11):3024-35. PubMed ID: 19887553
[TBL] [Abstract][Full Text] [Related]
17. RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition.
van der Meer R; Song HY; Park SH; Abdulkadir SA; Roh M
Clin Cancer Res; 2014 Jun; 20(12):3211-21. PubMed ID: 24771642
[TBL] [Abstract][Full Text] [Related]
18. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
Park JE; Kim TS; Kim BY; Lee KS
Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
[TBL] [Abstract][Full Text] [Related]
19. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
[TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.
Giordano A; Liu Y; Armeson K; Park Y; Ridinger M; Erlander M; Reuben J; Britten C; Kappler C; Yeh E; Ethier S
PLoS One; 2019; 14(11):e0224420. PubMed ID: 31751384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]